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Background: Peritoneal dialysis (PD) solutions with reduced sodium content may have advantages for
hypertensive patients; however, they have lower osmolarity and solvent drag, so the achieved Kt/Vurea may be
lower. Furthermore, the increased transperitoneal membrane sodium gradient can influence sodium balance
with consequences for blood pressure (BP) control.
Study Design: Prospective, randomized, double-blind clinical trial to prove the noninferiority of total weekly
Kt/Vurea with low-sodium versus standard-sodium PD solution, with the lower confidence limit above the
clinically accepted difference of 20.5.
Setting & Participants: Hypertensive patients ($1 antihypertensive drug, including diuretics, or office
systolic BP $ 130 mm Hg) on continuous ambulatory PD therapy from 17 sites.
Intervention: 108 patients were randomly assigned (1:1) to 6-month treatments with either low-sodium
(125 mmol/L of sodium; 1.5%, 2.3%, or 4.25% glucose; osmolarity, 338-491 mOsm/L) or standard-sodium
(134 mmol/L of sodium; 1.5%, 2.3%, or 4.25% glucose; osmolarity, 356-509 mOsm/L) PD solution.
Outcomes: Primary end point: weekly total Kt/Vurea; secondary outcomes: BP control, safety, and
tolerability.
Measurements: Total Kt/Vurea was determined from 24-hour dialysate and urine collection; BP, by office
measurement.
Results: Total Kt/Vurea after 12 weeks was 2.53 6 0.89 in the low-sodium group (n5 40) and 2.97 6 1.58 in
the control group (n5 42). The noninferiority of total Kt/Vurea could not be confirmed. There was no difference
for peritoneal Kt/Vurea (1.70 6 0.38 with low sodium, 1.776 0.44 with standard sodium), but there was a
difference in renal Kt/Vurea (0.836 0.80 with low sodium, 1.20 6 1.54 with standard sodium). Mean daily
sodium removal with dialysate at week 12 was 1.188 g higher in the low-sodium group (P, 0.001). BP
changed marginally with standard-sodium solution, but decreased with low-sodium PD solution, resulting in
less antihypertensive medication.
Limitations: Broader variability of study population than anticipated, particularly regarding residual kidney
function.
Conclusions: The noninferiority of the low-sodium PD solution for total Kt/Vurea could not be proved;
however, it showed beneficial clinical effects on sodium removal and BP.
Am J Kidney Dis. 67(5):753-761. ª 2016 Fresenius Medical Care. Published by Elsevier Inc. on behalf of the
National Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://
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eritoneal dialysis (PD) as an established renalP replacement therapy should ensure solute clear-
ance, peritoneal ultraﬁltration, and the physiologic
homeostasis of electrolytes and alsomaintain acid-base
balance. Adequate dialysis is broadly deﬁned in terms
of dialysis dose, expressed as Kt/V. In addition, other
clinical outcomes deserve attention. For example,
effective control of hypertension is of importance
because cardiovascular complications are the most
common causes of death in dialysis patients.1,2
Serum sodium concentration is considered an
important regulatory factor for extracellular volume
status and blood pressure (BP) control.3-8 The potential
role of peritoneal sodium elimination in BP control has
been described for patients on continuous ambulatory
PD (CAPD) therapy.9 However, the sodium concen-
tration of currently available PD solutions allows only
minor diffusive sodium clearance, so that sodium
elimination mostly occurs through convection with
ultraﬁltration. Transperitoneal sodium removal affects
total-body sodium balance and extracellular sodium
concentration, with subsequent potential reductions of
hypervolemia, factors that are pivotal for BP control in
patients with chronic kidney disease.10-13 Using dial-
ysis ﬂuids with low and ultra-low sodium concentra-
tions of 120 and 98 mmol/L, respectively, Nakayama
et al showed that low sodium concentrations facilitate
diffusive net sodium removal over time.14,15 In both
studies, increased sodium removal led to a decrease in
mean arterial BP, whereas no major differences were
recorded for body weight and ultraﬁltration. Further-
more, enhanced diffusive elimination of sodium may
alleviate the dietary restriction of oral salt intake.16-20
Another study showed beneﬁts in BP, thirst, and
ﬂuid status using a glucose-compensated solution with
a sodium concentration of 115 mmol/L.21
The present study investigates whether a new PD
solution with a reduced sodium content of 125 mmol/L
enhances diffusive sodium elimination. The slightly
reduced osmolarity of the low-sodium solution might
also affect ultraﬁltration and thereby solute drag;
therefore, the possible effect on dialysis dose is worthy
of investigation. The objective of the present study was
to investigate the therapeutic noninferiority of the new
low-sodium solution compared to a standard PD solu-
tion using achieved dialysis dose (Kt/Vurea) as the
primary end point and BP control, safety, and tolera-
bility as secondary end points.
METHODS
Study Design
This was a prospective, controlled, randomized, double-blind,
multicenter phase 3 study comparing a low-sodium PD solution754with a standard-sodium PD solution (control group). Both solu-
tions were produced by Fresenius Medical Care, Bad Homburg,
Germany. A baseline visit was performed just before study start,
and further study visits were performed at 2, 6, 12, 18 6 1, and
25 6 1 weeks after baseline.
Study Approval and Informed Consent
The trial was conducted in 17 centers: 2 in Austria, 2 in Canada,
1 in Germany, 7 in Poland, and 5 in the Netherlands. The study
was approved by the relevant authorities of the participating
countries and the institutional review boards of the participating
study centers. Informed consent was obtained from each patient
prior to inclusion.
Patient Eligibility and Randomization
Eligible patients were 18 years or older, on CAPD therapy for at
least 3 months, treated with standard-sodium solution for at least 4
weeks prior to inclusion, and on at least one antihypertensive
drug (including diuretics) or showed an ofﬁce systolic
BP $ 130 mm Hg. Patients prone to hyponatremia and who had
peritonitis within 4 weeks prior to study start were excluded.
Detailed eligibility criteria are listed in Item S1 (provided as online
supplementary material). Randomization was centrally performed
by 1:1 block randomization and was stratiﬁed by center.
Treatment Intervention
Patients were randomly assigned to receive CAPD treatment
with either the low-sodium (125 mmol/L of sodium) or the
standard-sodium solution (134 mmol/L of sodium) for all bags of
the day over 6 months in a double-blinded manner. The 2 solutions
are identical except for the sodium and chloride content
(Table S1). Glucose concentration was not increased to compen-
sate for the lower osmolarity of the low-sodium solution. The
individual pre-existing dialysis prescriptions for 1.5%, 2.3%, or
4.25% glucose were maintained during the study unless changed
for medical reasons.
Objectives and Outcome Measures
Efﬁcacy
The primary study objective was to assess the noninferiority of
the low-sodium solution in comparison to the standard-sodium
solution regarding achieved dialysis dose. The primary outcome
measure was total weekly Kt/Vurea after a 12-week period using
the assigned PD solution, assessed using a peritoneal function
test.22 In brief, in order to measure solutes and calculate peritoneal
and renal Kt/V (summing up to total Kt/V), dialysate outﬂow and
urine covering 24 hours were collected, the volumes were deter-
mined, and a blood sample was taken.
Other efﬁcacy parameters were peritoneal and renal urea
clearance, residual kidney function, changes in BP, or changes in
the number or dosage of antihypertensive drugs. Glomerular
ﬁltration rate (GFR) was calculated as the mean of urea and
creatinine clearance, which in turn were determined from urine
volume and urine and plasma urea and creatinine concentrations.
Ofﬁce BP measurements were performed on all study visits as
described previously23; that is, in a seated position after 5 minutes
of rest, with the same arm, and repeated after an interval of 5minutes.
A digital BP device (M5-I or HEM-757 [both Omron]) was used.
Dosing of antihypertensive drugs was based on the deﬁned daily
dose (DDD) prescribed at the respective visit (extracted from the
Anatomical Therapeutic Chemical/DDD system). One DDD unit
reﬂects the assumed average maintenance dose per day for a drug
used for its main indication. Combination drugs without a DDD
were split into their components. Furthermore, effects of the low-
sodium solution on sodium balance were tested. Daily sodium
removal by dialysate was calculated as the sum of the differencesAm J Kidney Dis. 2016;67(5):753-761
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Figure 1. Patient flow in the study. Abbreviations: AE, adverse event; FA, full-analysis; PP, per-protocol; SAE, serious
adverse event.
Low-Sodium Peritoneal Dialysis Solutionof sodium content in the efﬂuents and fresh dialysate for each
individual bag used over 24 hours.
Daily sodium intake was assessed using a standard diet proto-
col. Nutritional and ﬂuid intakes were documented by the patient
on 3 consecutive days (2 weekdays and one Sunday or national
holiday) and analyzed centrally using validated nutrition software
(PRODI 5.0; Nutri-Science GmbH). Psychometric assessments of
thirst and desire for salt were performed using a visual analogue
scale ranging from 0 (no thirst or desire for salt) to 10 (unsatisﬁed
thirst or desire for salt). Daily ultraﬁltration and membrane
transporter status (dialysate to plasma concentration of creatinine
at 4 hours) were also documented.
Safety
Target variables for safety were patient withdrawal from
the study, treatment-emergent adverse events, adverse events
of speciﬁc interest (hyponatremia, deﬁned as serum
sodium # 130 mmol/L, and peritonitis), concomitant medication,
abnormal hematology and clinical chemistry measurements, serum
sodium concentration, and clinical signs of overhydration.
Sample Size Estimation
Sample size was estimated based on the hypothesis of non-
inferiority being deﬁned as a clinically acceptable difference in
total weekly Kt/Vurea of 20.5 with a 1-sided level of signiﬁcance
of 2.5% and 90% power. Clinical acceptability of this difference
was based on a previous study showing no effect on mortality.24
Expecting a slightly smaller mean Kt/Vurea at week 12 in the
low-sodium group (20.1) and assuming a common standard de-
viation of 0.55, a total of 82 patients was needed in the relevant
per-protocol population. With an anticipated dropout rate of
w40%, this increased to 120 patients.
Data Collection and Statistical Analysis
For primary analysis, a 2-sided 95% conﬁdence interval was
calculated for the difference in least-square means of the total
weekly Kt/Vurea between groups at week 12 (value for theAm J Kidney Dis. 2016;67(5):753-761low-sodium group minus the value for the standard-sodium
group). An analysis of covariance (ANCOVA) model was used
including adjustment for treatment group, country, and covariate
total weekly Kt/Vurea at baseline. If the lower conﬁdence limit for
total weekly Kt/Vurea difference was above the clinically accept-
able difference of 20.5, the null hypothesis could be rejected and
low sodium could be considered as noninferior.
For secondary variables, group comparisons were performed on
a descriptive basis using analogous ANCOVA models for
continuous and c2 tests for categorical data, both taking the
respective values at baseline and other predeﬁned covariates, as
appropriate, into account.
Subgroup analysis on patients with GFRs# 6 mL/min/1.73 m2
was performed in a post hoc analysis, but was deﬁned before
unblinding. Explorative hypothesis tests were carried out using a
2-sided signiﬁcance level, a, of 5%. If not stated otherwise,
descriptive statistics are given as number and percentage for cate-
gorical variables andmean6 standard deviation for continuous data.
All efﬁcacy analyses are presented for the per-protocol popu-
lation (no major protocol violation and in study for at least 12
weeks); safety results are presented for the full-analysis set.
All analyses were performed with SAS, version 8.2 (SAS
Institute Inc). Sample size calculation was conducted with nQuery
Advisor V5.0 (Statistical Solutions Ltd).
RESULTS
Patient Recruitment and Analysis Sets
A total of 109 patients were enrolled, 108 patients
were randomly assigned, and 8 patients dropped out
before study start due to patient preference (n 5 3) or
other reasons. The full-analysis set consisted of 49
patients on low-sodium and 51 patients on standard-
sodium solution. The per-protocol population (no
major protocol violation and on study for at least 12
weeks) comprised 40 patients in the low-sodium and 42755
Table 1. Patient Characteristics at Baseline According to
Dialysate Solution Type
Low Sodium
(n 5 49)
Standard Sodium
(n 5 51)
Age, y 55.0 6 13.9 55.0 6 14.8
Male sex 57% 45%
CAPD vintage, mo
Mean 6 SD 20.6 6 17.8 15.6 6 14.4
Median [IQR] 11.8 [7.3-34.1] 13.6 [4.1-21.5]
Diabetes types 1 and 2 33% 33%
Hypertensiona
Stage I 22% 39%
Stage II 51% 41%
Stage III 27% 16%
Severity grading missing 0% 4%
Systolic BP, mm Hg 1506 24 1456 22
Diastolic BP, mm Hg 90 6 14 88 6 16
Coronary heart disease 27% 26%
Congestive heart failure 6% 2%
Antihypertensive
medication, DDD
Mean 6 SD 5.56 5.2 5.5 6 4.0
Median [IQR] 4.0 [2.3-6.7] 5.0 [2.0-7.8]
Use of diuretics 67% 75%
Body weight, kg 75.3 6 15.3 71.3 6 16.1
Residual diuresis, mL/d
Mean 6 SD 8466 601 925 6 844
Median [IQR] 888 [427-1,227] 820 [363-1,463]
GFR, mL/min/1.73 m2
Mean 6 SD 4.86 6.3 5.3 6 6.0
Median [IQR] 3.3 [0.9-6.2] 4.2 [1.4-6.5]
Total weekly Kt/Vurea 2.58 6 1.23 2.68 6 1.13
Peritoneal weekly Kt/Vurea 1.67 6 0.35 1.76 6 0.43
D/P creatinineb 0.67 6 0.1 0.71 6 0.11
Ultrafiltration, mL/d
Mean 6 SD 6286 595 683 6 574
Median [IQR] 671 [300-900] 719 [400-1,100]
Note: Full-analysis set (N 5 100). Values for categorical vari-
ables are given as percentages; values for continuous variables,
as mean 6 SD or median [IQR].
Abbreviations and definitions: BP, blood pressure; CAPD,
continuous ambulatory peritoneal dialysis; DDD, defined daily
dose, based on the Anatomical Therapeutic Chemical/DDD
system; D/P, dialysate to plasma; GFR, glomerular filtration rate;
IQR, interrquartile range; SD, standard deviation.
aHypertension stage I, no impairment of vital organs; stage II,
partial impairment of vital organs; stage III, damage of vital
organs.
bAt the 4-hour time point.
Rutkowski et alpatients in the control group. One patient in each group
excluded from the per-protocol group due to protocol
violations withdrew after week 12 due to an adverse
effect/serious adverse event. Patient ﬂow and reasons
for withdrawal from the study are shown in Fig 1.
Baseline Data
Patient characteristics at study inclusion are given
in Tables 1 and S2. The 2 groups were comparable756regarding demographic and anthropometric data,
medical history, and comorbid conditions. Mean
baseline GFRs were relatively high in both groups
(.5 mL/min/1.73 m2), and some patients had residual
kidney function far above the threshold for the rec-
ommended initiation of dialysis therapy (maximum
observed baseline GFR was .30 mL/min/1.73 m2 in
both groups).
Primary Efﬁcacy Outcome: Total Weekly Kt/V
The primary efﬁcacy parameter was total weekly
Kt/Vurea after 12weeks of treatment. In the per-protocol
set, the mean value for total weekly Kt/Vurea
decreased slightly in the low-sodium group (from
2.69 6 1.29 to 2.53 6 0.89) and increased in the con-
trol group (from 2.75 6 1.17 to 2.97 6 1.58; Fig 2A).
The lower 1-sided 97.5% conﬁdence limit for a least-
square mean of 20.78 exceeded the clinically accept-
able difference (noninferiority margin) of (2)0.5.
Thus, statistical noninferiority of the investigated so-
lution versus the control solution for total weekly
Kt/Vurea could not be demonstrated (Table 2).
Secondary Efﬁcacy Outcomes
Total Kt/Vurea in Patients With GFRs# 6 mL/min/1.73 m
2
A post hoc efﬁcacy analysis in a subgroup of pa-
tients with GFRs # 6 mL/min/1.73 m2 (the recom-
mended threshold for initiating dialysis therapy
according to the European Best Practice Guide-
lines for PD25) showed the low-sodium solution to be
noninferior to the standard-sodium solution (Table 2).
Peritoneal Kt/Vurea
Values for mean peritoneal Kt/Vurea were nearly
unchanged during the course of the study (Fig 2B).
Calculated group differences for the change in peri-
toneal Kt/Vurea were close to zero for all models, with
the lower 1-sided 97.5% conﬁdence limit for least-
square mean of 20.14.
BP and Antihypertensive Medication
Systolic anddiastolicBPsdecreasedduring the course
of the study in the low-sodium group, whereas changes
in the control group were only marginal (Table 3). The
results adjusted for covariates showed a difference in
systolic and diastolic BPs at week 12 of 8.6 mm Hg
(P5 0.06) and 4.6 mm Hg (P5 0.05), respectively,
lower in the low-sodiumgroup than in the control group.
Because peritoneal membrane transport may affect
ultraﬁltration and diffusive sodium elimination and in
consequence, BP, this was included as a further co-
variate in an exploratory model. In this model
including the baseline ratio of dialysate to plasma
creatinine concentrations at the 4-hour time point as
an indicator of peritoneal transport status, we found
greater BP reduction with the low-sodium solutionAm J Kidney Dis. 2016;67(5):753-761
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Figure 2. (A) Total weekly Kt/Vurea, (B) peritoneal weekly
Kt/Vurea, and (C) glomerular filtration rate (GFR), all by study
group and study visit for the low-sodium and control groups
(mean 6 standard deviation).
Low-Sodium Peritoneal Dialysis Solution(P 5 0.03 and P 5 0.01 for systolic and diastolic BP,
respectively).
Over time, antihypertensive drug treatment
increased in both groups. However, the increase was
less in the low-sodium group than in the control group
(week 12; Table 3). Patients in the low-sodium group
required an increase in antihypertensive medication
less frequently (20% and 25% at week 12 and 25,
respectively) compared with those in the control
group (41% and 45% at weeks 12 and 25; c2 test:
week 12, P 5 0.02; week 25, P 5 0.04).
Sodium Balance, Residual Kidney Function,
Ultraﬁltration, and Clinical Parameters
All descriptive analyses of these parameters are
given in Table 3. Adjusted mean daily sodium removalAm J Kidney Dis. 2016;67(5):753-761with dialysate was signiﬁcantly higher in the low-
sodium group, taking baseline, country, and daily
ultraﬁltration into account (by 1.188 g [P , 0.001]
at week 12, by 0.979 g [P , 0.001] at week 25, cor-
responding tow3 g of sodium chloride at week 12 and
2.5 g at week 25). Mean serum sodium values
decreased more in the low-sodium group than
in the control group (change of 21.966 mmol/L
[P 5 0.005] at week 12 and20.799 mmol/L [P 5 0.3]
at week 25). Dietary salt intake did not change.
Thirst decreased in both treatment groups at all
visits, but was more pronounced in the low-sodium
group (P 5 0.07 between the treatment groups,
week 12). The difference in oral ﬂuid intake was
statistically signiﬁcant at week 25 (P 5 0.02), but not
at week 12 (P 5 0.2).
Urine production rate was signiﬁcantly lower at
week 12 in the low-sodium group than in the control
group (2190.4 mL; P 5 0.03). However, it increased
at week 25 compared to baseline in both groups, with
nonsigniﬁcant differences between groups. Mean
GFR decreased in the low-sodium group, with the
group difference of borderline statistical signiﬁcance
at week 12 (21.87 mL/min/1.73 m2; P 5 0.05); no
signiﬁcant difference was seen at week 25 (Fig 2C).
Most patients (low-sodium group, 89.9%; control
group, 90.2%) used 4 bags of PD solution per day
(equivalent to 8 L). Prescribed glucose concentrations at
baseline in the low-sodium and control groups were on
average 1.71% 6 0.25% and 1.68% 6 0.30%, respec-
tively, both with no major change throughout the study.
Compared to baseline, mean daily ultraﬁltration
decreased slightly at weeks 12 and 25 in the low-
sodium group, whereas it increased slightly at week
12 and then decreased at week 25 in the control group
(Table 3). In the adjusted analysis, the difference
between groups was borderline statistically signiﬁcant
at week 12 (P 5 0.05), but not at week 25.
There were no signiﬁcant differences between
groups for the other efﬁcacy parameters measured (ie,
membrane transporter status, psychometric assess-
ments of desire for salt, and nutritional parameters).
Safety Outcome
All safety data refer to the full-analysis set
(n 5 100). As shown in Table 4, 34 of 49 patients in
the low-sodium group and 31 of 51 patients in the
control group had 166 treatment-emergent adverse
events during the course of the study. Most adverse
events reported were mild and generally fully
reversible. In the low-sodium group, more patients
had treatment-emergent and drug-related adverse
events (mostly hyponatremia and peripheral edema)
than in the control group.
Five patients in the low-sodium group and 4 pa-
tients in the control group each had 6 adverse events757
Table 2. Total, Peritoneal, and Renal Kt/Vurea for Per-Protocol Population and Analyzed by GFR
Per-Protocol Population
Population With Baseline
GFR # 6 mL/min/1.73 m2
Population With Baseline
GFR . 6 mL/min/1.73 m2
Low Sodium
(n 5 40)
Standard Sodium
(n 5 42)
Low Sodium
(n 5 26)
Standard Sodium
(n 5 26)
Low Sodium
(n 5 14)
Standard Sodium
(n 5 16)
Total Kt/Vurea
Baseline 2.69 6 1.29 2.756 1.17 2.11 6 0.36 2.23 6 0.48 3.766 1.68 3.58 6 1.47
Wk 12 2.53 6 0.89 2.976 1.58 2.12 6 0.53 2.39 6 0.56 3.296 0.93 3.91 6 2.18
Group difference at
wk 12 (95% CI)
20.396 (20.780 to 20.012) 20.200 (20.473 to 0.074) 20.751 (21.732 to 0.230)
Peritoneal Kt/Vurea
Baseline 1.72 6 0.36 1.766 0.44 1.67 6 0.33 1.77 6 0.42 1.816 0.40 1.74 6 0.48
Wk 12 1.70 6 0.38 1.776 0.44 1.68 6 0.38 1.76 6 0.40 1.726 0.40 1.78 6 0.51
Group difference at
wk 12 (95% CI)
20.038 (20.141 to 0.066) 20.011 (20.116 to 0.137) 20.124 (20.320 to 0.072)
Renal Kt/Vurea
Baseline 0.97 6 1.24 0.996 1.17 0.45 6 0.34 0.46 6 0.40 1.956 1.66 1.84 6 1.50
Wk 12 0.83 6 0.80 1.206 1.54 0.43 6 0.39 0.63 6 0.52 1.576 0.86 2.12 6 2.14
Group difference at
wk 12 (95% CI)
20.355 (20.697 to 20.014) 20.182 (20.393 to 0.028) 20.639 (21.540 to 0.262)
Note: Peritoneal weekly Kt/V was calculated as the (sum of urea clearance of all bags of day) 3 7/urea distribution volume. Renal
weekly Kt/V was calculated as (renal urea clearance/urea distribution volume) 3 7 3 1.44. Total weekly Kt/V is the sum of peritoneal
weekly Kt/V and renal weekly Kt/V. Unless otherwise indicated, values are mean 6 standard deviation.
Abbreviations: CI, confidence interval; GFR, glomerular filtration rate.
Rutkowski et althat led to permanent discontinuation of study medi-
cation. In the control group, more patients had
adverse events that were classiﬁed as severe, serious,
or fatal. Twenty-six patients had a total of 40 serious
adverse events: 15 occurred in the low-sodium group
and 25 in the control group. Of these serious adverse
events, 3 deaths occurred during the course of the
trial, one in the low-sodium group (exacerbation of
coronary heart disease) and 2 in the control group
(peritonitis/colon carcinoma and peritonitis); all 3
were judged as unlikely to be related or not related to
trial medication.
Six events of hyponatremia in 3 patients of the low-
sodium group were reported. Four further events (3 in
the low-sodium and one in the control group) of
hyponatremia with sodium levels of exactly
130 mmol/L were noted. These events were catego-
rized as mild or moderate, and all resolved by the end
of the study. In the low-sodium group, a reduction in
serum sodium level from baseline to week 12 (mean
change of 22.54 mmol/L) and to week 25 (mean
change of 22.16 mmol/L) was observed, whereas
there was almost no change in the control group at
either of these visits (20.03 and 20.56 mmol/L,
respectively). All other biochemical parameters
showed no signiﬁcant changes from baseline or be-
tween groups. Vital signs and clinical examinations
did not raise safety concerns. None of the patients
showed serious signs of overhydration or relevant
changes in body weight during the study.758DISCUSSION
The present study investigated whether a PD so-
lution with reduced sodium content provides a dial-
ysis dose (total weekly Kt/Vurea) comparable to that of
a standard PD solution. Noninferiority of the low-
sodium solution in comparison to the standard solu-
tion could not be established for total Kt/Vurea.
Whereas a standard deviation of 0.55 was assumed
for sample size calculation, results showed a standard
deviation between 0.9 and 1.6 at week 12. Nonethe-
less, the mean total weekly Kt/Vurea (2.53 in the
low-sodium and 2.97 in the control group after 12
weeks) was clearly above the target of a total weekly
Kt/Vurea $ 1.7, as deﬁned by current guidelines.
25,26
The changes in total Kt/Vurea may be explained by
differences in residual kidney function between
groups, which in turn seemed to be related to high
residual kidney function in certain patients. Approx-
imately one-third of the patients had GFRs . 6 mL/
min/1.73 m2 at baseline; extreme GFRs as high as
56.5 mL/min/1.73 m2 were also recorded in the
course of the study. Although some patients had
cardiac insufﬁciency (New York Heart Association
class I or II), which is a possible reason to initiate
dialysis therapy earlier than commonly recom-
mended, this does not fully explain why that many
patients with high GFRs were initiated on dialysis
therapy. In these patients, changes in total Kt/Vurea are
greatly inﬂuenced by the changes in kidney function.
This is supported because noninferiority of theAm J Kidney Dis. 2016;67(5):753-761
Table 3. BP Parameters and Sodium and Fluid Status
Low-Sodium Solution Standard-Sodium Solution
Baseline Wk 12 Wk 25 Baseline Wk 12 Wk 25
No. of patients 40 40 35 42 42 37
Systolic BP, mm Hg 1526 24 1416 22 143 6 23 1486 21 1476 23 1446 23
Diastolic BP, mm Hg 91 6 14 86 6 11 85 6 13 90 6 14 90 6 13 88 6 15
Antihypertensive
medication, DDD
Mean 6 SD 5.36 5.2 5.7 6 5.4 6.06 5.4 5.6 6 3.9 6.6 6 3.8 6.3 6 3.7
Median [IQR] 3.7 [2.3-6.7] 4.5 [2.1-7.6] 4.7 [2.2-8.3] 5.3 [2.0-7.5] 6.1 [3.5-8.0] 6.0 [3.0-7.8]
Mean glucose
applied, %
1.746 0.27 1.75 6 0.31 1.69 6 0.26 1.67 6 0.29 1.70 6 0.30 1.67 6 0.25
Peritoneal
ultrafiltration,
mL/24 h
6576 569 602 6 707 6216 520 698 6 548 741 6 664 640 6 676
Urine volume,
mL/24 h
Mean 6 SD 9156 594 868 6 660 1,022 6 700 977 6 858 1,0816 808 1,0156 791
Median [IQR] 902 [541-1,303] 893 [416-1,313] 890 [513-1,537] 835 [455-1,463] 1,000 [522-1,600] 930 [588-1,300]
GFR, mL/min/1.73 m2
Mean 6 SD 5.466 6.75 4.45 6 4.69 4.67 6 4.12 6.01 6 6.39 6.48 6 8.32 6.02 6 9.36
Median [IQR] 3.79 [1.20-6.34] 3.91 [0.70-6.44] 4.05 [1.71-6.72] 4.47 [2.01-7.31] 4.64 [2.52-7.85] 3.57 [2.55-6.11]
Sodium removal
urine, g/d
1.866 1.35 1.79 6 1.96 1.99 6 1.88 2.22 6 3.50 2.04 6 2.10 2.09 6 2.38
Sodium removal
dialysate, g/d
3.106 1.92 2.71 6 2.13 2.67 6 1.66 1.68 6 1.65 1.75 6 2.05 1.32 6 2.02
Serum sodium, mEq/L 140.26 3.03 137.86 3.59 138.36 3.95 139.66 3.53 139.46 2.83 138.46 3.30
Thirst, mm on VAS 46.76 22.8 30.4 6 25.4 32.2 6 23.4 50.3 6 23.7 41.4 6 28.0 39.8 6 28.9
Desire for salt, mm on
VAS
27.16 19.4 23.6 6 25.3 22.2 6 21.5 26.2 6 19.3 26.8 6 20.9 24.2 6 19.4
No. of patients 23 28 29 27 32 30
Dietary water intake,
mL/d
1,4006 751 1,1676 515 9956 463 1,1386 503 1,1236 499 1,0526 554
Dietary salt intake, g/d 2.416 1.40 2.64 6 1.69 2.77 6 1.17 2.36 6 0.98 2.37 6 1.14 2.24 6 1.27
Note: All data are derived from the per-protocol population. Values are given as mean 6 SD or median [IQR].
Abbreviations and definitions: BP, blood pressure; DDD, defined daily dose based on the Anatomical Therapeutic Chemical/DDD
system; GFR, glomerular filtration rate; IQR, interquartile range; SD, standard deviation; VAS, visual analogue scale ranging from 0 (no
thirst, no desire for salt) to 100 mm (unquenchable thirst or desire for salt).
Low-Sodium Peritoneal Dialysis Solutionlow-sodium solution was shown for the per-protocol
subgroup of patients with GFRs # 6 mL/min/
1.73 m2. Separate analysis of peritoneal Kt/Vurea
showed that the actual dialysis dose achieved with the
2 PD solutions was nearly identical, with standard
deviations lower than 0.5, as anticipated.
Residual kidney function and ultraﬁltration were
signiﬁcantly lower in the low-sodium group after 3
months, but not after 6 months. Although the slightly
lower osmolarity of the solution under investigation
could explain the reduced ultraﬁltration, one would
then expect that diuresis should increase due to an
increase in vascular ﬁll volume. However, the decrease
in serum sodium level might result in lower thirst and
ﬂuid intake, potentially reducing ﬂuid overload and, in
turn, urine excretion, as shown in studies with pure salt
restriction27 or as regularly seen in incident dialysis
patients. Hypervolemia and high BP are closely
associated with sodium uptake and sodium balance.27Am J Kidney Dis. 2016;67(5):753-761Treatment with the reduced-sodium PD solution
showed increased sodium elimination by the perito-
neal membrane, in line with results from a study using
a similarly composed low-sodium PD solution.28 This
results in decreased serum sodium levels, systolic BP,
and diastolic BP, as well as antihypertensive medica-
tion dosage. Our results are consistent with ﬁndings
from studies that used different sodium concentrations
and prescription schedules.14,15,21 Unfortunately, bio-
impedance data were not available for assessment of
hydration status, analysis of how this may be inﬂu-
enced by the low-sodium solution, and whether it af-
fects efﬁcacy and safety outcomes.
In comparison to some studies, the sodium con-
centration we used (125 mmol/L) is very moderate
in terms of reduced-sodium dialysate solutions.
This low-sodium solution was designed for con-
tinuous use in all daily exchanges. This avoids
physiologic ﬂuctuations caused by alternating759
Table 4. Summary of Adverse Events According to
Solution Type
Low Sodium
(n 5 49)
Standard
Sodium (n 5 51)
General
TEAEs 94 72
Severe AEs 4 9
Drug related AEsa 15 2
AEs that led to solution
discontinuation
6 6
Serious AEsb 15 25
Deaths 1 2
TEAEs accounting for $5% of
TEAEs in either group
Peritonitis 5 11
Peripheral edema 5 3
Catheter-related infection 0 4
Decrease in hemoglobin 3 4
Hyponatremia (#130 mmol/L) 9 1
Drug-related AEsa
Peripheral edema 4 0
Hyponatremia 6 0
Hypokalemia 2 0
Fluid retention 0 1
Restless leg syndrome 1 0
Hoarseness 1 0
Hypotension 1 0
Orthostatic hypotension 0 1
Note: Full-analysis set (N 5 100).
Abbreviations: AE, adverse event; TEAE, treatment-emergent
adverse event.
aRelationship probable or possible.
bAEs leading to death, hospitalization, or serious deterioration
in health status.
Rutkowski et alnormal- and low-sodium exchanges, as seen in
other trials using lower sodium concentrations but
restricting use to one bag per day. We did not
observe any clinically relevant adverse effects
related to ultraﬁltration despite not compensating
for the decrease in total osmolarity. Such compen-
sation seems to be necessary for solutions with
sodium content of 115 or 102 mmol/L, as previ-
ously described.21
Ultraﬁltration, volume status, and BP are related to
peritoneal transport properties.29 Because high trans-
porters tend to have lower ultraﬁltration when treated
with CAPD, an improved potential for diffusive so-
dium removal might compensate for the lower
convective removal. This could explain why the effect
of the low-sodium solution on BP is even more pro-
nounced when peritoneal permeability is taken into
account.
Both solutions showed a good general safety proﬁle.
As expected, more adverse events with hyponatremia
were seen in the low-sodium group, all of which
were judged to be mild or moderate and had resolved
by the end of the study. These results suggest that760hyponatremia may occur with the use of a low-sodium
CAPD solution and thus sodium should be closely
monitored, particularly in conjunction with actual re-
sidual kidney function. Use of a low-sodium solution
for only part of the daily prescribed bags allows ﬂexible
adjustment according to the patient’s individual needs.
Several limitations of the study should be acknowl-
edged. Unexpectedly, our study population showed
broader variability than published clinical data. This
could have been accounted for by a larger sample size or
more stringent exclusion criteria. Furthermore, perito-
neal Kt/Vurea could have been considered as a primary
end point instead of total Kt/Vurea in order to directly
evaluate the dose provided by the PD solution.
In conclusion, a PD solution with a reduced sodium
content of 125 mmol/L was investigated for its ability
to provide adequate dialysis and to improve BP
control in PD patients. Although results of the study
did not show statistical proof of noninferiority for the
primary efﬁcacy parameter total Kt/Vurea due to
variability of residual kidney function, noninferiority
was demonstrated for patients with GFRs # 6 mL/
min/1.73 m2 and for peritoneal clearances. With
respect to sodium removal and BP control, a signiﬁ-
cant improvement could be seen with the low-sodium
PD solution. Evaluation of safety parameters revealed
that treatment with the new solution was safe and well
tolerated. Low-sodium PD solutions may be a viable
alternative to standard solutions for hypertensive
long-term PD patients.
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